Table 2 Humanized mice models for EBV vaccines.
From: Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Year | Vaccine formulation and immunization route | Challenge strain | Results | Ref. |
|---|---|---|---|---|
2008 | αDEC-205-EBNA-1(aa400-641) + poly(I:C) i.p. twice at one month interval | None | EBNA-1 specific T cells and anti-EBNA-1 antibodies were detected | |
2015 | rAd5F35/BZLF-1-transduced human DCs i.p. once or twice at a 2-week interval | NoneA | Prolonged survival to EBV-LPD | |
2018 | immunogenic particles containing EBNA-1 + poly(I:C) i.p. twice at a 4-week interval | B95-8 | Significant protection against EBV challenge | |
2022 | Passive infusion of antibodies purified from mice immunized with gH/gL/gp42 + gp350D123 or gH/gL + gp350D123 ferritin nanoparticles 20 µg of mIgG per gram of mouse i.p. at day −1, day 0, and day 1 | B95-8 | Only one of six mice in each group received immune IgG had transient low-level viremia | |
2022 | Passive infusion of antibodies purified from mice immunized with gH/gL 60 mer nanoparticle 500 mg of total IgG per mouse i.p. 48 h pre EBV challenge | B95-8 | Purified antibodies from immunized mice protected humanized mice from lethal EBV challenge |
